Influenza viruses resistant to neuraminidase inhibitors

Acta Biochimica Polonica

Volumn 61, Issue 3, 2014, Pages 505-508

  Nitsch Osuch, Aneta ^a   Brydak, Lidia Bernadeta ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Influenza; Neuraminidase inhibitors; Resistance

Indexed keywords

AVES; ORTHOMYXOVIRIDAE;

ANTIVIRUS AGENT; ENZYME INHIBITOR; OSELTAMIVIR; SIALIDASE; ZANAMIVIR;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CHILD; DRUG EFFECTS; HUMAN; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; INFLUENZA, HUMAN; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CHILD; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; ZANAMIVIR;

EID: 84907705912     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2014_1871     Document Type: Review

References (33)

1. Advisory Committee on Immunization Practices (ACIP) (2014) Prevention and Control of Seasonal Influenza with Vaccines. Recommendations of the Advisory Committee on Immunization Practices-United States, 2013-14. http://www.cdc.gov/flu/professionals/acip/index.htm.(accessed 24 April 2014).
2. Chotpitayasununondh T, Ungchusak K, Hanshaoworakuln W (2005) Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 11: 1158-1159.
3. European Medicines Agency (EMA) (2013) Updated review of influenza antiviral medicinal products for potential use during pandemic by the Committee for Medical Products for Human Use (CHMP) of the European Medicine Agency. (accessed 12 April 2013).
4. Govorkova E, Baranovich T, Seiler P, Armstrong J, Burnham A, Guan Y, Peiris M, Webby R, Webster R, (2013) Antiviral resistance among highly pathogenic influenza A (H5N1) viruses isolated worldwide in 2002-2012 shows need for continued monitoring. Antiviral Research 98: 297-304.
5. Gubareva LV (2004) Molecular mechanisms of influenza viruses resistance to neuraminidase inhibitors. Virus Res 103: 199-203.
6. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC (1998) Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178: 1257-1262.
7. Hayden FG, Gubereva LV, Monto AS (2000) Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 343: 1282-1289.
8. Hayden FG, Belshe R, Villanueva C (2004) Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis. J Infect Dis 189: 440-449.
9. Hurt AC, Lee RT, Leang SK, Cui L, Deng YM, Phuah SP, Caldwell N, Freeman K, Komadina N, Smith D, Speers D, Kelso A, Lin RT, Maurer-Stroh S, Barr IG (2011) Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation Eurosurveillance 16: pii19884.
10. de Jong MD, Tran TT, Troung HK, VoMH, Smith GJ (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353: 2667-2672.
11. Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC (2008) Emergence of resistance to oseltamivir among influenza A (H1N1) viruses in Europe. Eurosurveillance 13: 1-3.
12. Le Q, Kiso M, Someya K, Sakai T, Nguen T, Ngyuen K, Pham N (2005) Avian flu: isolation of drug resistant H5N1 virus. Nature 437: 1108.
13. Mc Kimm-Breschikin JL (2000) Resistance of influenza viruses to neuraminidase inhibitors. Antivir Res 46: 1-17.
14. Mc Kimm-Breschikin JL, Williams J, Barrett S, Jachno K, McDonald M, Mohr PG, Saito T, Tashiro M (2013) Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. J Antimicrob Chemother 68: 2210-2221.
15. Monto AS, Fleming DM, Henry D (1999) Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infection. J Infect Dis 180: 254-261.
16. Monto AS, McKimm-Breschikin JL, Macken C, Hampson A, Hay A (2006) Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50: 2395-2402.
17. Moscona AM: Neuraminidase inhibitors for influenza (2005) New Engl J Med 353: 1363-7134.
18. Nicholson KG, Aoki FY, Osterhaus AD (2000) Efficacy and safety of oseltamivir in treatment of acute influenza a randomized controlled trial. Lancet 355: 1845-1850.
19. Nicoll A, Ciancio B, Kramarz P (2008) Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. Eurosurveillance 13: 3-6.
20. Okomo-Adhiambo M, Sleeman K, Lysen C, Nguyen XT, Xu X, Klimov AI, Gubareva LV (2013) Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during 2011 Southern Hemisphere season. Influenza Other Respir Viruses 7: 645-658.
21. Reece PA (2007) Neuraminidase inhibitor resistance in influenza viruses. J Med Virol 79: 1577-1586.
22. Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubavera LV (2013) R292K substitution and drug susceptibility of influenza A (H7N9) viruses. Emerg Infect Dis 19: 1521-1524.
23. Thorlund K, Award T, Boivin G, Thabane L (2011) Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis 11: 134-142.
24. Tran TH, Nguen TL, Luong TS, Pham PM (2004) Avian influenza A (h5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179-1188.
25. Treanor JJ, Hayden FG, Vrooman PS (2000) Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 283: 1016-1024.
26. Varghese JN, Smith PW, Sollins SL, Blick TJ (1998) Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure 6: 735-746.
27. Ward P, Small I, Smith Jm Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an avian influenza pandemic. J Antimicrob Chemother 55: i5-25.
28. Whitley Rj, Hayden FG, Reisinger KS, Young N, Dutkowski R (2001) Oral oseltamivir treatment of influenza in children. J Pediatr Infect Dis 30: 127-133.
29. World Health Organization (WHO) (2014) Issues new guidelines for the avian flu virus.www.who.ont (accessed 24 April 2014).
30. World Health Organization (WHO) (2007) Avian influenza situation in Egypt - update, 18 January 2007.www.who.int/csr/don/2007.(accessed 24 April 2014).
31. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova E (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 80: 8787-8795.
32. Yen HL, Monto AS, Webster RG, Govorkova EA (2001) Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A /Vietnam/1203/04 influenza virus in mice. Antimicrob Agents Chemother 192: 665-672.
33. Yuen KY, Wong SS (2005) Human infection by avian influenza A H5N1. Clin Microbiol Rev 11: 189-199.